Vir Biotechnology Inc is a commercial-stage immunology company focused on treating and preventing infectious diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product...
Still in a dangerous zone but breaking a resistance level after shuffling with supporting volume and oscillators returning to positive territory
Buy - $11.3
First target - $14.45
Second target - around $22
If the stock reaches these numbers we will talk about additional goals, right now it's too early to talk.
Not a recommendation of course!
For those of you who...
Bullish
Fundamental
- High inflationary Macro environment / no fear sentiment
- Funds Accumulation
- Positive PE
- Positive PEG
- Positive P/FCF
- Top Sector / Industry
- Moderate floats
- High short interest / 7 days + 58%
- Impressive sales ?
Technical
- - Momentum Theory Indicator - N/A on the weekly
- Price action formation ( falling wedge )
- Yet...
After the very good results of the first quarter,the stock reacted well. The hepatitis cases remain under control. The company's balance sheet is clean and this gives hope for the future...
There is something that market is wrong about. The VIR and its blockbuster drug. This drug earns $1-1.5B per Q.
+ they are clinical stage company with Huuge innovative pipeline in HBV and HIV - treatments and VACCINES!
And market prices them like @#$! while they will earn around their own 1x market cap in 2022 and will sit with so much cash, that the current...
Analysis for VIR
Two falling wedges can be seen to have formed in this current down move
As in the previous down move, price temporarily moves out of the channel before moving back up
This is what's occurring now with this second falling wedge
I do expect a big break out at this huge support area
HC Wainwright & Co. Maintains Buy on Vir Biotechnology, Raises Price Target to $200
CEO of Covid antibody maker Vir Biotech says its treatment ‘stands up well’ to all variants
KEY POINTS:
- Vir Biotechnology CEO George Scangos said the monoclonal antibody Covid treatment it developed with GlaxoSmithKline “stands up well” to all variants.
- The companies announced...
The VIR weekly chart shows an obvious resemblance between Phase 1 and Phase 2, so we can expect a breakout to $80-90 zone on good news, for example Q4 Earning report with Covid treatmengt Sotrovimab sales worldwide or good trial readouts from their developing products, when the Phase 2 completed.
Note: VIR share price is heavily undervalued, the fair share value...
Description: VIR is trending higher and in an uptrend meaning that highs are getting higher and lows are getting higher. The uptrend line on the chart and the Trending Band Indicator (which measures trend) supports the Long Position.
Stats:
1. Ideal buy range: $49.6 - $53
2. Take profit: $68.9
3. Stop Loss: $47.15
4. Risk To Reward: 1 / 5
5. Accuracy Rating: 78%
VIR has a couple of interesting products testing in the pipeline.
The one that caused the spike in Jan is for hepatitis B treatment.
And the selloff today is caused by the pause in the enrollment of late-stage trial testing of their Covid19 antibody.
So it seems it is safe to assume that it will return above previous resistance of 53. With 80's as a first target,...
VIR is sitting on the 1.618 fib circle. Ideally, price will fill the wick at $140. I wouldn't be surprised if price surpasses that target as the overall picture shows that price is currently in a major wave 3. A break and retest over $81 would confirm the next leg
Initial Data from Ongoing Phase 1 Trial of VIR-3434 for Chronic Hepatitis B Virus Infection Demonstrates Significant and Rapid Reduction in Hepatitis B Surface Antigen
Data from the first blinded cohort of eight patients, two of whom received placebo and six of whom received a single dose of 6 mg of VIR-3434, showed that six of eight patients achieved a mean...
